This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

Figure 1



TOSTED. COBBER



WO 00/37102



FIGURE 2

GCATGGATCCATGGGACTGAGTAACATTCTCTTTG

1	<u>ATG</u> GGACTGAGTAACATTCTCTTTGTGATGGTCCTCCT
39	GCTCTCTGGTGCCTCCTTGAAAAGTCAGGCATATTTCAATGAGA
86	CTGGAGAACTGCCGTGCCATTTTACAAACTCGCAGAACCTAAGCCTG
133	GATGAGCTGGTCATATTTTGGCAGGACCAGGATAACCTGGTTCTCTA
181	CGAGCTATACCGAGGCCAAGAGAGCCTCATAATGTTAATTCCAAG
227	TATATGGGTCGCACAAGCTTTGACCAGGCCACCTGGACCCTGAGACT
274	CCACAACGTTCAAATCAAGGACAAGGGCTCATATCAATGTTTCATC
321	CATCATAAAGGGCCGCATGGACTTGTTCCTATCCACCAGATGAGTTC
368	TGACCTATCATTGCTTACTTCAGTCAACCTGAAATAAACCTAC
415	TTACTAATCACACAGAAAATTCTGTCATAAATTTGACCTGCTCATCT
462	ACACAAGGCTACCCAGAACCCCAGAGGATGTATATGTTGCTAAATA
509	CGAAGAATTCAACCACTGAGCATGATGCTGACATGAAGAAATCTCA
556	AAATAACATCACGGAACTCTACAATGTATCAATCAGGGTGTCTCTT
602	CCCATCCCTCCCGAGACAAATGTGAGCATCGTCTGTGTCCTGCAACTT
649	GAGCCAAGCAAGACACTGCTTTTCTCCCTACCTTGTAATATAGATGC
696	AAAGCCACCTGTGCAACCCCCTGTCCCAGACCACATCCTCTGGATTGC
743	AGCTCTACTTGTAACAGTGGTCGTTGTGTGTGGGATGGTGTCCTTTGT
<i>7</i> 90	AACACTAAGGAAAGAAGAAGCAGCCTGGCCCCTCTAATGA
837	ATGTGGTGAAACCATCAAAATGAACAGGAAGGCGAGTGAACAAAC
884	TAAGAACAGAGCAGAAGTCCATGAACGATCTGATGATGCCCAGTGT
931	GATGTTAATATTTTAAAGACAGCCTCAGATGACAACAGTACTACAG
	GACAACAGTACTACAG
978	ATTTT <u>TAA</u> TTAAAGAGTAAACTCC

ATTTTTAAGTCGACATGC




ı.	CACCECECTE	CGGCCGCTCT.	AGAACTAGTG	GATCLATIFICE	ACTGAGTAAC
- 51	ATTCTCTTTG	GGATGGTCCT	CCTGCTCTCT	GGTGCTGCCT	CCTTGAAAAG
101	TCAGGCATAT	TTCAATGAGA	CTGGAGAACT	GCCGTGCCAT	TTTACAAACT
151	CGCAGAACCT	AAGCCTGGAT	GAGCTGGTCA	TATTTTGGCA	GGACCAGGAT
201	AACCIGGTIC	TCTACGAGCT	ATACCGAGGC	CAAGAGAAGC	CTCATAATGT
251	TAATTCCAAG	TATATGGGTC	GCACAAGCTT	TGACCAGGCC	ACCTGGACCC
301	TGAGACTCCA	CAACGTTCAA	ATCAAGGACA	AGGGCTCATA	TCAATGTTTC
351	ATCCATCATA	AAGGGCCGCA	TGGACTTGTT	CCTATCCACC	AGATGAGTIC
401	TGACCTATCA	GTGCTTGCTA	ACTTCAGTCA	ACCTGAAATA	AACCTACTTA
451	CTAATCACAC	AGAAAATTCT	GTCATAAATT	TGACCTGCTC	ATCTACACAA
501	GGCTACCCAG	AACCCCAGAG	GATGTATATG	TTGCTAAATA	CGAAGAATIC
551	AACCACTGAG	CATGATGCTG	ACATGAAGAA	ATCTCAAAAT	AACATCACGG
601	AACTCTACAA	TGTATCAATC	AGGGTGTCTC	TTCCCATCCC	TCCCGAGACA
651	AATGTGAGCA	TCGTCTGTGT	CCTGCAACTT	GAGCCAAGCA	AGACACTGCT
701	TTTCTCCCTA	CCTTGTAATA	TAGATGCAAA	GCCACCTGTG	CAACCCCCTG
751	TCCCAGACCA	CATCCTCTGG	ATTGCAGCTC	TACTTGTAAC	AGTGGTCGTT
801	GTGTGTGGGA	TGGTGTCCTT	TGTAACACTA	AGGAAAAGGA	AGAAGAAGCA
851	GCCTGGCCCC	TCTAATGAAT	GTGGTGAAAC	CATCAAAATG	AACAGGAAGG
901	CGAGTGAACA	AACTAAGAAC	AGAGCAGAAG	TCCATGAACG	ATCTGATGAT
951	GCCCAGTGTG	ATGTTAATAT	TTTAAAGACA	GCCTCAGATG	ACAACAGTAC
1001	TACAGATTTT	TAAGTCGACC	TCGAGGGGG	GCCCGGTACC	AGCTTTTGTT


7.1


WO 00/37102

PCT/GB99/04200


Figure 4: Comparison of the nucleotide sequence of CD86(i) with the published sequence for porcine CD86.











7/36



















FIGURE 5-1

Contig Murine B7-2 AATTCTGTCATAAATTTGACCTGCTCATCTACACAAGGCTACCCAGAACCCCAGAGGATGTATA Porcinc CD68(i) AATTCTGGCATAAATTTGACCTGCACGTCTAAGCAAGGTCACCCGAAACCTAAGAAGATGTATT Human B7.2 AATGTGTACATAAATTTGACCTGCTCATCTATACACGGTTACCCAGAACCTAAGAAGATGAGTG TTTTGCTAAVTACNAAGAATTCAACTAHTGAGTATGATGVTAACATGCAGAAATCTCAAGATAA TGTTGCTAAATACGAAGAATTCAACCACTGAGCATGATGCTGACATGAAGAAATCTCAAAATAA TTCTGATAACT-----AATTCAACTAATGAGTATGGTGATAACATGCAGATATCACAAGATAA TTTTGCTAAGAACCAAGAATTCAACTATCGAGTATGATGGTATTATGCAGAAATCTCAAGATAA TGTCACAGAACTGTTCAGTATCTCCAACAGCCTCTCTTTTCATTCCCGGATGGTGTGGGCAT TGTCACAGAACTGTACGACGTTTCCATCAGCTTGTCTGTTTCATTCCCTGATGTTACGAGCAAT ATGACCATCGTCTGTGTTCTGGAAACTGAGNCAANCAAGACNCNGCTTTTCTCCHHACC GTGAGCATCGTCTGTGTCCTGCAACTTGAGCCAAGCAAGACACTGCTTTTCTCCCTACCTTGTA ATGACCGTTGTGTGTTCTGGAAACGGAGTCAATGAAGA--TTTCCTCCAAACCTCTCA ATGACCATCTTCTGTATTCTGGAAACTGA-----CAAGACGCGGCTTTTATCTTCACCTTTCT ATATAGATCHAGAGEHHCCINNNCAACCICCINNCCCAGACCACATECNNTGGATTACAGCTET ATATAGATGCAAAGCCACCTGTGCAACCCCCTGTCCCAGACCACATCCTCTGGATTGCAGCTCT ATTICACTCAAGAGTTTCC----ATCTCCTCAAACGTATTGGAAG---GAGATTACAGCTTC CTATAGAGCTTGAGGACCCT---CAGCCTCC---CCCAGACCACATTCCTTGGATTACAGCTGT ACTINNAACAGIGGICVIIVIVIGIGIGAIGGIGIICINIVIAATICTAIGGAAANNNAAGAAG ACTIGIAACAGIGGICGITGIGIGGGGATGGIGCCTTIGIAACACTAAGGAAA---AGGAAG AGTT---ACTGTGGCCCTCCTTGTGATGCTGCTC---ATCATTGTATG---TCACAAGAAG ACTTCCAACAG---TTATTATATGTGTGATGGTTTTCTGTCTAATTCTATGGAAATGGAAGAAG AAGAAGCAGCCTVGCAVCTCTAATAAATGTGGNNNAACCAHCAAAATGGAGAGGGANGNGAGTG AAGAAGCAGCCTGGCCCCTCTAATGAATGTGGTGAAACCATCAAAATGAACAGGAAGGCGAGTG CCGAATCAGCCTAGCAGGCCCAGCAA-----CACAGCCTCTAAGTTAGAGCGGGA---TAGT-AAGAAGCGGCCTCGCAACTCTTATAAATGTGG---AACCAACACAATGGAGAGGGGAAGAGAGTG AACAAACTAAGAACAGAGCAGAAGTCCAT-GAACGATCTGATGATGCCCAGTGTGATGT AACG--CTG---ACAGAGAGA----CTATCAACCIGAAGGAACT--TGAACCCCA-AACAGACCAAGAAAAAGAGAAAAAATCCATATACCTGAAAGATCTGATGAAGCCCAGCGTGTTTT TAANADITINNAAGACAGCITCANNNGACAAAAGTNIITACANNITTITTAADINNAGAGTNAAGNI TAATATTTTAAAGACAGCCTCAGATGACAACAGTACTACAGATTTTTAAGT---GCTTCA--GCAAAA--CCAAATGCAGAGTGAAG-



FIGURE 6

Contig Murine CD86 Porcine CD86(i) Human CD86 Porcine CD86



60 70 80 90 100 110

SLSELVVFWQDQQKLVLYEHYLGTEKLDSVNAKYLGRTSFDRNNWTLRLHNVQIK
SLDELVIFWQDQDNLVLYELYRGQEKPHNVNSKYMGRTSFDQATWTLRLHNVQIK
SLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIK
SLSELVIFWQDQDNLVLYELYRGQEKPHNVNSKYMGRTSFDQATWTLRLHNVQIK

120 130 140 150 160


...|.|...|...|...|...|


DMGSYDCFIQKKPPTGSIILQQTLTELSVIANFSEPETKLAQNVTGNSGINLTCT

DKGSYQCFIHHKGPHGLVPIHQMSSDLSVLANFSQPEINLLTNHTENSVINLTCS

DKGLYQCIIHHKKPTGMIRTHQMNSELSVLANFSQPEIVPISNITENVYINLTCS

DKGSYQCFIHHKGPHGLVPIHQMSSDLSILANFSQPEINLLTNHTENSVINLTCS








FIGURE 7-1




FIGURE 7-2






FIGURE 8a








FIGURE 8a-1





1,5


FIGURE 8b

10 20 30 40 50 60 Contig bovine CD40 protein MVRLPLQCLFWGFFLTAVHSEPATACGEKQYPVNSLCCDLCPPGQKLVNDCTEVSKTECQ human CD40 protein MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECL murine CD40 protein MVSLPRLCALWGCLLTAVHLGQCVTCSDKQYLHDGQCCDLCQPGSRLTSHCTALEKTQCH 70 80 100 110 120 Contig bovine CD40 protein SCGKGEFLSTWNREKYCHEHRYCNFNLGLRIQSEGTLNTDTICVCVEGQHCTSHTCESCT human CD40 protein PCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCV murine CD40 protein PCDSGEFSAQWNREIRCHQHRHCEFNQGLRVKKEGTAESDTVCTCKEGQHCTSKDCEACA 130 140 150 160 170 180 Contig bovine CD40 protein PHSLCLPGFGVKQIATGLLDTVCEPCPLGFFSNVSSAFEKCHRWTSCERKGLVEQHVGTN human CD40 protein LHRSCSPGFGVKQIATGVSDTICEPCFVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGIN murine CD40 protein QHTPCIPGFGVMEMATETTDTVCHPCPVGFFSNQSSLFEKCYPWTSCELKNLEVLQKGTS 190 200 210 220 230 240 Contig bovine CD40 protein KTDVVCGFQSRMRTLVVIPVIMGVLFAVLLVSACIRNITKKhuman CD40 protein KTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPINKAPHP-murine CD40 protein QINVICGLKSRMRALLVIPVVMGILITIFGVFLYIKKVVKKPKDNEMLPPAARRQDPQEM 250 260 270 280 Contig 1111 bovine CD40 protein WLKGRIPWRRL--IRRIFPA--PTRLSGARDLMLVSAGRPGGRQ human CD40 protein NFPDDLPGSNTAAFVQETLHGCQPVTQEDGKESRISVQERQ murine CD40 protein --- EDYPGHNTAAPVQETLHGCQFVTQEDGKESRISVQERQVTDSIALRPLV














l	MGLSNILFVM VLLLSGAASL KSQAYFNETG ELPCHFTNSQ
41	NLSLDELVIF WQDQDNLVLY ELYRGQEKPH NVNSKYMGRT
81	SFDQATWTLR LHNVQIKDKG SYQCFIHHKG PHGLVPIHQM
121	SSDLSLLANF SQPEINLLTN HTENSVINLT CSSTQGYPEP
161	QRMYMLLNTK NSTTEHDADM KKSQNNITEL YNVSIRVSLP
201	IPPETNVSIV CVLQLEPSKT LLFSLPCNID AKPPVQPPVP
241	DHILWIAALL VTVVVVCGMV SFVTLRKRKK KQPGPSNECG
281	ETIKMNRKAS EQTKNRAEVH ERSDDAQCDV NILKTASDDN
321	STTDF•LKSK L

































Figure 14a

FIGURE 14b









Peptide 6 coated plates







FIGURE 15a












Peptide conc



B




D




Porcine B7-2

Murine B7-2









The state of the s


COSCOLO COSCOLO




FIGURE 17a















FIGURE 17b



Murine CD86

FIGURE 18






FIGURE 19

Day 1: Immunisation of C57BL-6 mice with whole ovalbumin (50 micrograms) in Complete freunds adjuvant (CFA)



Day 14: First immunisation with chimeric peptide (100 micrograms) i.v.

Day 21: Second immunisation with chimeric peptide (100 micrograms) i.v.

Day 28: Third immunisation with chimeric peptide (100 micrograms) i.v.



Day 32: Mice rendered diabetic by injection of streptozotocin i.p.




Day 36: Transplantation of 1000 porcine pancreatic islets under the kidney capsule of diabetic mice



Day 37 onwards: Survival of islets assessed by measuring blood glucose levels


DOBESSOS LOGIEOI








30 / 36 FIGURE 21






CDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPW

120


130



100


90

1	MVRLPLQCLL	WGCFLTAVHP	EPPTSCKENQ	YPTNSRCCNL
41	CPPGQKLVNH	CTEVTETECL	PCSSSEFLAT	WNREKHCHQH
81	KYCDPNLGLQ	VQREGTSKTD	TTCVCSEGHH	CTNSACESCT
121	LHSLCFPGLG	VKQMATEVSD	TICEPCPVGF	FSNVSSASEK
161	CQPWTSCESK	GLVEQRAGTN	KTDVVCGFQS	RMRALVVIPI
201	TLGILFAVLL	VFLCIRKVTK	EQETKALHPK	TERQDPVETI
241	DLEDFPDSTA	PVQETLHWCQ	PVTQEDGKES	RISVQERQ




33 / 36

FIGURE 23-1



IVVIFGASNI LWMVFAVSQN VKVEIFPEDK MIAQIGDSAS
LTCSAPDCES SLSFSWRTQI DSPLNGKVKT NGTRSTLVMN
PVSFENEHSY LCTVSCGNLK GERGIQVEIY SFPKDPEIHW
SSLPEVGKPV TVRCLVPDVY PVEKLEIELL KDNHSMVSQN
FLELIDIKSK ETKSLEFTFT PTEEDIGKAI VCQATLIIDG
QPSVKTTPEK MQVYISPKDP VISVNPSTSL QEGDSMMMTC
TSEGLPAPQI SWSKKLDNGD QQLLSGNATL TLIAMRMEDS
GIYVCEGVNP VGTNRKEVEL TVQVAPRDTT ISVNPSSTLE
EGSSVNMTCS SDGFPAPKIL WSKKLRDGNL EPLSENTTLT
LTSTKMEDSG IYVCEGINQA GINRKEVELI IQAAPKDLQL
TAFPSESVKE GDTVIISCTC GNVPPTLIIL KKKAETGDTV
LKSTDGAYTI HRARLADAGV YECESKNEIG LQLRSITLDV
KGRESNKDYF SSELLVLYCA SSLIIPAIGV IIYFARKANM
RGSYSLVDAQ KSKV•



7



36 / 36

1	MGLSNILFVM	VLLLSGAASL	KSQAYFNETG	ELPCHFTNSQ
41	NLSLDELVIF	WQDQDNLVLY	ELYRGQEKPH	NVNSKYMGRT
81	SFDQATWTLR	LHNVQIKDKG	SYQCFIHHKG	PHGLVPIHQM
121	SSDLSLLANF	SQPEINLLTN	HTENSVINLT	CSSTQGYPEP
161	QRMYMLLNTK	NSTTEHDADM	KKSQNNITEL	YNVSIRVSLP
201	IPPETNVSIV	CVLQLEPSKT	LLFSLPCNID	AKPPVQPPVP
241	DHILWIAALL	VTVVVVCGMV	SFVTLRKRKK	KQPGPSNECG
281	ETIKMNRKAS	EQTKNRAEVH	ERSDDAQCDV	NILKTASDDN
321	STTDF			